33. Include paediatric R&D and product deployment research and analysis in the next Access to Medicine Index, highlighting critical paediatric treatment R&D issues and actions pharmaceutical companies are taking to address those, by January 2021.

34. Explore additional methods of including paediatric access issues in the following editions of the Access to Medicine Index and to do so as part of the next Access to Medicine Index Methodology review process, by December 2021.